Modality
Bispecific Ab
MOA
Menini
Target
JAK1
Pathway
JAK/STAT
WilmsGBM
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
~Jun 2017
→ ~Sep 2018
NDA/BLA
~Dec 2018
→ ~Mar 2020
Approved
Jun 2020
→ Mar 2028
ApprovedCurrent
NCT07116795
2,819 pts·GBM
2020-06→2028-03·Terminated
2,819 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2028-03-282.0y awayPh3 Readout· GBM
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Approved
Termina…
Catalysts
Ph3 Readout
2028-03-28 · 2.0y away
GBM
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07116795 | Approved | GBM | Terminated | 2819 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| MLY-3531 | Mineralys | NDA/BLA | JAK1 | |
| Kemanesiran | Sage | Approved | JAK1 | |
| VYG-2970 | Voyager | Phase 3 | JAK1 | |
| TXG-6755 | 10x Genomics | Approved | CD123 |